Meme Kanseri Tedavileri ve Tiroid Fonksiyonları Üzerine Etkileri

Li, X. et al. Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta- analysis and systematic review. Clin. Cancer Res. 22, 3971–3981 (2016).

Hartmann, L. C. et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N. Engl. J. Med. 340, 77–84 (1999).

Jakub, J. W. et al. Oncologic safety of prophylactic nipple- sparing mastectomy in a population with BRCA mutations: a multi- institutional study. JAMA Surg. 153, 123–129 (2018).

Jakub JW, Peled AW, Gray RJ, et al. Oncologic safety of prophylactic nipple-sparing mastectomy in a population with BRCA mutations: A multi-institutional study. JAMA Surg 2018;153:123-129. doi:10.1001/jamasurg.2017.3422.PMID:28903167.

Terry, M. B. et al. Risk- reducing oophorectomy and breast cancer risk across the spectrum of familial risk. J. Natl Cancer Inst. 111, 331–334 (2019).

Kotsopoulos, J. et al. Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers. J. Natl Cancer Inst. 109, djw177 (2017).

Mai, P. L. et al. Risk- reducing salpingo- oophorectomy and breast cancer risk reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199). JNCI Cancer Spectr. 4, pkz075 (2019).

Milne, R. L. & Antoniou, A. C. Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers. Endocr. Relat. Cancer 23, T69–T84 (2016).

Demark-Wahnefried W, Goodwin PJ. To your health: how does the latest research on alcohol and breast cancer inform clinical practice?. J Clin Oncol 2013;31:1917-1919. doi:10.1200/JCO.2013.49.0466.PMID:23569302.

Newcomb PA, Kampman E, Trentham-Dietz A, et al. Alcohol consumption before and after breast cancer diagnosis: associations with survival from breast cancer, cardiovascular disease, and other causes. J Clin Oncol 2013;31:1939-1946. doi:10.1200/JCO.2012.46.5765.PMID:23569314.

Visvanathan K, Fabian CJ, Bantug E, et al. Use of endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline update. J Clin Oncol 2019;37:3152-3165. doi:10.1200/JCO.19.01472.PMID:31479306.

Winzer BM, Whiteman DC, Reeves MM, et al. Physical activity and cancer prevention: a systematic review of clinical trials. Cancer Causes Control 2011;22:811 826. doi:10.1007/s10552-011-9761-4.PMID:21461921.

Cummings SR, Tice JA, Bauer S, et al. Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst 2009;101:384-398. doi:10.1093/jnci/djp018.PMID:19276457.

Cuzick, J. et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta- analysis of individual participant data. Lancet 381, 1827–1834 (2013).

Cuzick, J. et al. Tamoxifen for prevention of breast cancer: extended long- term follow- up of the IBIS- I breast cancer prevention trial. Lancet Oncol. 16, 67–75 (2015). This paper describes the long- term follow- up of the IBIS- I trial participants who received 5 years of preventive tamoxifen and shows that the protection against breast cancer is maintained for at least 20 years.

Nelson, H. D., Smith, M. E., Griffin, J. C. & Fu, R. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 158, 604–614 (2013).

Skandarajah, A. R. et al. Patient and medical barriers preclude uptake of tamoxifen preventative therapy in women with a strong family history. Breast 32, 93–97 (2017).

DeCensi A, Puntoni M, Guerrieri-Gonzaga A, et al. Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia. J Clin Oncol 2019;37:1629-1637. doi:10.1200/JCO.18.01779.PMID:30973790.

Lazzeroni M, Puntoni M, Guerrieri-Gonzaga A, et al. Randomized placebo controlled trial of low-dose tamoxifen to prevent recurrence in breast noninvasive neoplasia: a 10-year follow-up of TAM-01 study. J Clin Oncol 2023;41:3116-3121. doi:10.1200/JCO.22.02900.PMID:36917758.

DeCensi A, Puntoni M, Johansson H, et al. Effect modifiers of low-dose tamoxifen in a randomized trial in breast noninvasive disease. Clin Cancer Res 2021;27:3576-3583. doi:10.1158/1078-0432.CCR-20-4213.PMID:33608319.

Vogel, V. G. et al. Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxife

Freedman, A. N. et al. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J. Clin. Oncol. 29, 2327–2333 (2011).

Cuzick, J. et al. Use of anastrozole for breast cancer prevention (IBIS- II): long- term results of a randomised controlled trial. Lancet 395, 117–122 (2020). This paper describes the long- term follow- up of a randomized controlled trial of anastrozole or placebo for breast cancer prevention and shows that 5 years of anastrozole confers at least 10 years of preventive benefit.

Cuzick, J. et al. Anastrozole for prevention of breast cancer in high- risk postmenopausal women (IBIS- II): an international, double- blind, randomised placebo- controlled trial. Lancet 383, 1041–1048 (2014).

Goss, P. E. et al. Exemestane for breast- cancer prevention in postmenopausal women. ne (STAR) P-2 trial: preventing breast cancer. Cancer Prev. Res. 3, 696–706 (2010).

Goss PE, Ingle JN, Ales-Martınez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;364:2381-2391. doi:10.1056/ NEJMoa1103507.

Cuzick J, Sestak I, Forbes JF, et al.; IBIS-II investigators. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2014;383:1041-1048. doi:10.1016/S0140-6736(13)62292-8.PMID:24333009.